hVIVO's Mo Khan on the company’s breakthrough year
Vox Markets speaks to Mo Khan, chief executive of fast-growing clinical research specialist (HVO ), about the factors behind an expectation-beating year, and how rising awareness of its unique human challenge model points to major growth ahead.
0:29 Highlights of the trading update, and drivers behind an exceptional ahead-of-expectations performance
2:04 Market drivers behind the company’s strong performance, including a growing realisation among drug developers of the value of human challenge trials
3:59 Delivering the huge order backlog and growing the pipeline of potential new deals, and the coming launch of new challenge models
6:35 hVivo’s unique model, and why as a world leader in human challenge trials it’s becoming a critical component of drug development
8:04 Discusses the recent Venn Life Sciences consultancy contract win
9:02 Using strengthening cash generation to start paying a dividend alongside continued investment in growth
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.